New contract, page-23

TDA may have a different list but what I have been following

	Column 1	Column 2	Column 3
1	Development Name	Type	Indication
2	SAR339658	Anti-VLA 2 mAb	Multiple Sclerosis
3	SAR228810	Anti-protofibrillar AB mAb	Alzheimer’s disease
4	SAR252067	Anti-LIGHT mAb	Crohn’s disease
5	Alirocumab	PCSK9 mAb	Cholesterol
6	SAR113244	Anti-CXCRS mAb	Systemic lupus erythematosu
7	Dupilumab	IL4RαmAbAtopic	Dermatitis; Asthma; Nasal polyposis

Dupilumab has 3 target indications so you could almost count that as three. Though best leave it at one until you see some dosages for later stage trials being over 300mg which is not a bad rule of thumb cut off point for viscosity/volume/concentration exceeding PFS and AIDs capability

First cab off the rank is hopefully Alirocumab and Sanofi-REGN chasing Amgen and monthly dosing (Awaits reporting on Choice 1 program) Then its Dupilumab by my ruler

Guess with this in the bag UNS may let the cat out of the bag re Sanofi using Finesse for some of the drugs with as Sarilumab, Alirocumab etc. As you point out kar18na the announcement points a finger towards REGN

Good work to those loyal folk who hung around.